When docetaxel is on the UK shortage register: the four sourcing routes an oncology pharmacy actually uses.

Docetaxel shortages are cyclical, not accidental. A taxane concentrate, single-source API chemistries, a small handful of global finished-product lines, and the combination produces supply gaps roughly every two to three years. When the gap hits, an oncology pharmacy has about a fortnight to find a route that is legal, clinically acceptable, and documented — before the Monday chemotherapy list comes around.

What the DHSC shortage register actually says.

The UK Department of Health and Social Care (DHSC) maintains a medicine shortage register, historically stratified into Tier 2 (a national shortage with mitigation guidance) and Tier 3 (a severe shortage with active clinical management). In parallel, the MHRA issues Medicine Supply Notifications (MSN) to the NHS, setting out the expected duration, alternatives, and clinical guidance for a specific product gap.

Docetaxel has appeared on that register at multiple points during the 2020s. The causes have varied: API supply disruption at a large contract manufacturer, a regulatory hold at a finished-product site, the commercial withdrawal of a generic brand, or a downstream cold-chain and release backlog after a single site went offline. The register tells you a shortage exists. It rarely tells you how to get stock this week.

Two practical things to check the moment you see docetaxel on the register. First, the MSN's suggested mitigation — is it a direct substitute (paclitaxel, nab-paclitaxel, cabazitaxel with oncology MDT sign-off), or is the NHS expected to import? Second, the register's tier — a Tier 2 with a two-month horizon is a procurement problem; a Tier 3 with a four-week stock-out warning is a clinical one. The sourcing route you pick needs to match that horizon, not the aspiration.

The four legitimate sourcing routes.

When the licensed UK supply is constrained, an NHS oncology pharmacy has four routes to get docetaxel onto a chemotherapy list. Each has its own regulatory footprint, its own paperwork stack and its own timeline.

1. Named-patient import from a licensed EU or Indian source

Under regulation 167 of the Human Medicines Regulations 2012, a UK prescriber can request an unlicensed medicinal product to meet the special clinical needs of an individual patient. The UK Wholesale Dealer's Licence holder (WDA(H) with the unlicensed-medicine authorisation) submits an MHRA import notification, sources from a WHO-GMP manufacturer abroad, and releases the product at destination. This is the most common shortage-response route for oncology cytotoxics. See named-patient import, UK.

2. MHRA Specials via a UK Specials manufacturer or importer

An MHRA-licensed Specials manufacturer can produce an unlicensed medicinal product, or a Specials importer can source one from a regulated market with surplus. The Specials route is the workhorse for aseptic-unit compounded chemotherapy, but for a finished concentrate like docetaxel it usually collapses into the named-patient import route above.

3. Parallel import from an EU market with surplus

A Parallel Import Licence (PIL) holder can source docetaxel packs from an EU market where supply is adequate and repackage for the UK. Post-Brexit, the PLPI (Product Licence for Parallel Import) mechanics have tightened, but the route still operates and is often the first call when a Continental market holds stock that the UK does not.

4. Direct WHO-GMP supply to a WDA(H) importer

A UK importer with an active WDA(H) can source docetaxel from a validated Indian WHO-GMP supplier that has run the UK lane before. This is the fastest emergency route: 48 to 72 hours from purchase order to wheels-up out of Mumbai, with a full documentation pack prepared at source.

What is not a route: a direct hospital purchase from a manufacturer abroad without a UK import licence in the chain. It is a breach of regulation, it will not clear at Heathrow, and it will expose the pharmacy to a Responsible Pharmacist incident that outlasts the shortage.

Clinical considerations when you switch supplier.

Docetaxel is a concentrate for solution for infusion with clinical specifics that do not travel between brands automatically. A new supplier's product is not a drop-in replacement for the licensed UK line — these are the items an oncology pharmacist reconfirms before the first vial is hung.

• Strength and vial volume. Historically 20mg/0.5mL and 80mg/2mL; newer polysorbate-80-free and single-vial options sit at 20mg/1mL and 160mg/8mL. Confirm the vial volume before the aseptic unit rewrites the worksheet.
• Polysorbate-80 vehicle. Most docetaxel formulations use polysorbate-80 as the solubilising vehicle. The hypersensitivity-reaction risk is real, and pre-medication with dexamethasone 8mg twice daily for three days, starting the day before docetaxel, is the standard SmPC recommendation. Newer polysorbate-80-free lines change the premed conversation — check the specific product.
• DEHP leaching from PVC infusion sets. Docetaxel extracts the di(2-ethylhexyl) phthalate plasticiser from PVC infusion lines. Non-PVC sets (polyolefin or polyethylene-lined) are standard practice; a short PVC segment at the patient end is an accepted mitigation where a fully non-PVC line is not available.
• Extravasation. Docetaxel is a moderate-risk vesicant. The extravasation SOP for the new brand should match the unit's existing taxane protocol — usually dry-cold packs, hyaluronidase is not indicated for taxanes.
• Neutropenic fever risk. G-CSF prophylaxis thresholds do not change with supplier. What can change is the infusion-reaction profile: a polysorbate-80-free line has different premed requirements and different extravasation handling.
• Reconstitution and admixture stability. The concentrate is typically 15-25°C and protected from light; the admixed infusion has its own stability (commonly 4 hours at room temperature, longer at 2-8°C with specifics per SmPC). Confirm against the new supplier's SmPC, not the legacy one.

Timelines — standard and emergency.

The question every procurement lead asks first is how fast. The honest answer depends on which route, which supplier relationship, and whether the MHRA import notification is fresh or previously filed for the same molecule-and-supplier pair.

Standard import — 14 to 21 days

1. Prescriber request and oncology pharmacy review — same day.
2. UK importer MHRA import notification — same-day submission, 28-day review window (expedited on urgent clinical need; often clears inside a week for a known molecule).
3. Purchase order placed with the Indian supplier — 24 to 48 hours.
4. Batch pick or production slot, QC release — 5 to 10 days.
5. Cold-dolly or ambient-with-excursion-tolerance dispatch, BOM-LHR air freight — 8 to 10 hours in transit, plus handover.
6. UK importer release and hospital delivery — 24 hours.

Emergency import — 7 to 10 days

When the clinical need is active (the next chemotherapy list), the same chain compresses. The MHRA import notification runs on an urgent-clinical-need basis, the Indian supplier ships from batches already on hand rather than a new production slot, and air freight is booked on the next available BOM-LHR rotation rather than the weekly consolidator. In our experience, seven to ten days from PO to hospital receipt is the realistic emergency timeline for an established supplier who has cleared the UK documentation before. Forty-eight to seventy-two hours is achievable only on a same-batch reorder where the MHRA notification is already approved and the carton is literally sitting on the ramp.

The paperwork to demand from a new supplier.

A UK importer's Responsible Person reviews an import file before the consignment lands, not after. For a shortage-driven docetaxel supply from a new source, the pack should contain every item below — and should be circulated electronically before the carton leaves Mumbai.

1. WHO-GMP certificate of the specific manufacturing site, with a minimum six months residual validity.
2. CDSCO Certificate of Pharmaceutical Product (CoPP) in WHO format — or the equivalent regulator's CoPP if sourcing from an EU-GMP site.
3. Batch-specific Certificate of Analysis (CoA). HPLC assay, related substances, water content, residual solvents, sterility and endotoxin. Signed by the manufacturer's authorised QC head. A generic product CoA is not enough.
4. Certificate of Origin from an accredited chamber of commerce in India (or FIEO). Some UK importers additionally request Indian MEA apostille.
5. Free Sale Certificate confirming the product is freely exportable from India.
6. Stability summary. 24 or 36 months on the concentrate, with the admixed-solution stability data referenced.
7. Pack insert and artwork in a format the UK importer can cross-reference against the SmPC.
8. Cold-chain or temperature logger data. Docetaxel finished concentrate is generally ambient 15-25°C protected from light, but the shipper configuration should be thermally validated and continuously logged in transit.
9. Manufacturer declaration for the named-patient consignment, naming the patient count and the UK importer's Responsible Person.
10. MHRA import notification attachment — the manufacturer-side fields prepared, so the UK importer's Responsible Person only has to complete the importer-side fields.

If any of these arrive after dispatch, the file is not complete. For the documentation-chain fundamentals, see WHO-GMP, CDSCO and the paper trail that clears customs.

The commercial reality of a shortage premium.

Shortage cycles produce a shortage premium. The unit price on an emergency import is routinely two to four times the licensed UK contract price, and sometimes higher for a Tier 3 event. That is a real number, and it is worth being honest about two things that come with it.

First, the premium is not the supplier being opportunistic — it is the cost of a faster batch, a dedicated cold-dolly, a weekend air-freight slot, and the regulatory overhead of a one-off import. A supplier offering a shortage price at parity to the licensed contract price is a supplier who is either pricing a loss-leader or cutting a corner you will eventually notice.

Second, a shortage is exactly the moment a pharmacy is most tempted to try an unfamiliar supplier because they answered the phone first. The discipline is the opposite: pick a supplier who has run the UK lane before, has the import notification template on file, and can circulate the documentation pack before the purchase order. The difference between a seven-day emergency import and a fourteen-day one is almost never the manufacturing step — it is whether the paperwork was ready.

A final note on therapeutic substitution. Paclitaxel, nab-paclitaxel and cabazitaxel are sometimes proposed as substitutes for docetaxel. They are genuinely different molecules with different regimens, toxicity profiles and evidence bases. Substitution is an oncology MDT decision with a prescriber's written rationale, not a procurement workaround. The import route usually wins for a short-horizon shortage; substitution is for a longer one.

FAQ

Can an NHS trust import docetaxel directly from India during a shortage?

Not without a UK import licence in the chain. The regulation-167 named-patient route requires a UK Wholesale Dealer's Licence holder (WDA(H)) with the unlicensed-medicine import authorisation, who submits the MHRA import notification, releases the product at destination, and supplies the pharmacy. An Indian WHO-GMP supplier sits on the manufacturer side of that chain; a direct trust-to-manufacturer shipment would be a regulatory breach. In practice, the trust's procurement team nominates a Specials importer and we supply into that importer.

How fast can docetaxel actually be imported when the MHRA register lists a shortage?

For an established supplier relationship with a current MHRA import notification, seven to ten days from purchase order to hospital receipt is the realistic emergency timeline. The chain is roughly same-day PO, 24-48 hours to Indian supplier dispatch, 8-10 hours BOM-LHR air freight, and 24 hours for UK importer release. Faster than that — 48 to 72 hours — requires the exact batch already in-stock and the MHRA notification already approved. Standard-timeline imports run 14 to 21 days.

What is the difference between MHRA Specials and named-patient import for docetaxel?

The unlicensed-medicines routes overlap but differ in mechanism. Named-patient import under regulation 167 is triggered by an individual prescriber's request for a specific patient, routed through a WDA(H) importer. MHRA Specials is supply of an unlicensed medicinal product to meet the special clinical needs of a patient, via an MHRA-licensed Specials manufacturer or importer. For a finished docetaxel concentrate in shortage, the routes usually converge — the Specials importer is the WDA(H) holder doing the named-patient import.

Which documents are non-negotiable on a first-time docetaxel import from a new supplier?

WHO-GMP certificate of the manufacturing site, CDSCO CoPP, batch-specific CoA (not generic), Certificate of Origin from an accredited chamber, Free Sale Certificate, stability summary, pack insert, cold-chain logger data for the shipper configuration, manufacturer declaration for the named-patient consignment, and the manufacturer-side fields of the MHRA import notification. If any of those arrive after dispatch, the pack is incomplete and the UK importer's Responsible Person will delay release.